Sulbutiamine

Sulbutiamine at a Glance

Sulbutiamine is a synthetic, highly fat-soluble derivative of thiamine (vitamin B1) — two thiamine molecules bridged by a disulfide bond and esterified. It was developed in Japan in the 1960s, originally as a beriberi treatment, and is sold as Arcalion and Enerion.

The engineering problem it solves is specific: ordinary thiamine is water-soluble and crosses the blood–brain barrier poorly. Making it lipophilic lets it reach the brain and raise thiamine and thiamine-phosphate levels there in a way plain vitamin B1 does not. Once absorbed it is converted back to thiamine, so it is best understood as a centrally-targeted delivery form of B1 rather than a distinct drug.

The framing that matters: sulbutiamine is not an essential nutrient. It has no dietary source, no RDA and no deficiency state — so there is no repletion benefit to fall back on. If the goal is simply correcting thiamine status, ordinary dietary thiamine does that. Sulbutiamine is used when a central effect beyond nutritional repletion is wanted.

The honest bottom line: the human evidence is small, old, mostly uncontrolled, and concentrated in clinical populations rather than healthy adults. This is a “does it help tired, unwell people” story — not a validated “extra energy for the well” story. After roughly 50 years of availability, there is still no well-designed RCT for the nootropic claims that drive its over-the-counter sales.

What It’s Used For

Ranked by how well the evidence actually holds up:

• Asthenia / functional fatigue — the indication it was designed for, with the largest dataset. But the largest study is uncontrolled, so the design is weak exactly where the volume is greatest.
• Nocturnal enuresis in children — oddly, the single best-designed trial on this compound, and in an indication nobody buys it for.
• Fatigue in multiple sclerosis — one small open study.
• Diabetic polyneuropathy — nerve conduction improved; how patients felt did not.
• Alzheimer’s adjuvant — a small sequenced add-on trial with donepezil.
• Psychogenic erectile dysfunction — one uncontrolled study of 20 men.
• Cognitive enhancement in healthy adults — rat models and mechanism only.

Be sceptical of the mass-market “energy, focus and motivation” claim. There is no randomized trial of cognition, energy or motivation in healthy adults — the population that actually buys it. Two further cautions the marketing omits: a case report documents tolerance and compulsive escalation of use, and sulbutiamine is flagged in sports doping-control as a possible masking or ergogenic agent.

One framing point worth stating plainly: sulbutiamine addresses the symptom of fatigue, not its cause. Persistent asthenia deserves a medical workup before self-treatment.

How It Works

Everything follows from the delivery trick. Thiamine is the cofactor for pyruvate dehydrogenase, transketolase and α-ketoglutarate dehydrogenase — the enzymes that let cells burn glucose aerobically. Brain tissue is highly dependent on that pathway, but water-soluble thiamine reaches it inefficiently. Sulbutiamine’s disulfide-bridged, esterified structure is lipophilic enough to cross, then converts back to thiamine centrally ^{12Reference 12Van Reeth O · 1999ReviewPharmacologic and therapeutic features of sulbutiamine — reviewView study →}.

Raising brain thiamine is only part of the story, though, and the rest is what distinguishes sulbutiamine from a B1 tablet. Chronic dosing upregulates D1 dopamine receptors in prefrontal and cingulate cortex, and it modulates glutamatergic transmission by reducing kainate receptor density ^{7Reference 7Trovero F et al. · 2000AnimalEvidence for a modulatory effect of sulbutiamine on glutamatergic and dopaminergic cortical transmissions in the rat brain — animal studyView study →}. That dopaminergic shift is the plausible basis for the motivation and drive effects users describe — and also for the agitation and insomnia that show up as side effects.

It also potentiates cholinergic transmission in hippocampus and prefrontal cortex, which is the rationale for the Alzheimer’s add-on work, and behaves as a thiol/disulfide antioxidant under oxygen–glucose deprivation ^{8Reference 8Bizot JC et al. · 2005Chronic treatment with sulbutiamine improves memory in an object recognition task and reduces some amnesic effects of dizocilpine — animal studyView study →}.

The practical consequence: the plasma half-life is short, around five hours, so studied regimens use daily and often divided dosing rather than one large dose. And because it is fat-soluble, taking it with a meal containing some fat is reasonable.

Pharmacology & Research

Sulbutiamine is a synthetic, highly lipophilic thiamine (vitamin B1) derivative — two thiamine molecules bridged by a disulfide bond and esterified — engineered to cross the blood–brain barrier far more readily than thiamine itself and to raise thiamine and thiamine-phosphate levels inside the brain. It is not an essential nutrient and there is no dietary source or deficiency to correct; it is used as a drug/supplement for asthenia (functional fatigue), low motivation and mild cognitive complaints. The human evidence base is small, old, mostly uncontrolled and concentrated in clinical (asthenic, diseased) populations rather than healthy adults — so this is a “does it help sick/tired people” story, not a validated “extra energy for the well” story. Because the compound is off-patent and cheap, there is little industry incentive for the large randomized trials the field openly says are still missing.

Evidence by IndicationStrength of support · Beta

Support is an experimental score I’m building — a composite weighted by study type (human > animal > in vitro > review) and study volume. It’s a beta: a fast way to rank strength of evidence at a glance, not a validated metric. Each application links down to its write-up.

01Asthenia / functional fatiguePromising58%Large but uncontrolled observational series + narrative reviews; the core indication, weak design

02Nocturnal enuresis (children)Promising52%One recent 3-arm RCT (n=450); comparable to imipramine, single study, unusual indication

03Fatigue in multiple sclerosisPromising46%Single small open study (n=26), no placebo control

04Diabetic polyneuropathyShaky42%Small open RCT (n=30); objective nerve conduction improved, symptoms did not

05Alzheimer’s adjuvantShaky40%Small randomized add-on to donepezil; episodic memory/daily activity signal

06Psychogenic erectile dysfunctionShaky33%Single small open study (n=20), no control

07Cognitive enhancement in healthy adultsShaky22%Rat memory models + mechanism only; no healthy-adult RCT

Mechanisms

Pharmacokinetics

Sulbutiamine is a lipid-soluble dimer of thiamine (isobutyryl thiamine disulfide) built specifically to overcome thiamine’s poor blood–brain-barrier penetration; oral dosing raises thiamine and thiamine-phosphate esters in the brain in a way plain thiamine does not ^{4,12Reference 4Sevim S et al. · 2017Clinical trialSulbutiamine shows promising results in reducing fatigue in patients with multiple sclerosis — open clinical studyView study →Reference 12Van Reeth O · 1999ReviewPharmacologic and therapeutic features of sulbutiamine — reviewView study →}. It is absorbed orally, converted to thiamine in the body, and reported to have a relatively short plasma half-life (on the order of a few hours), which is why studied regimens use daily (sometimes divided) dosing. Because the active systemic species is ultimately thiamine, it is functionally a centrally-targeted thiamine delivery vehicle rather than a distinct long-acting drug.

Clinical trials

Registered-trial and published-trial activity is sparse and mostly historical; as an off-patent molecule sold OTC in many markets, it attracts little sponsored trial investment, and reviewers repeatedly note that adequately powered randomized controlled trials are still lacking ^{2Reference 2Starling-Soares B et al. · 2020ReviewRole of the synthetic B1 vitamin sulbutiamine on health — reviewView study →}.

Last checked: August 2026.

Dietary Sources

Sulbutiamine has no dietary source — it is a fully synthetic molecule and does not occur in food. It was developed in Japan in the 1960s (originally as a beriberi treatment) by joining two thiamine molecules with a disulfide bridge and adding isobutyryl ester groups, which makes the resulting compound fat-soluble so it can cross the blood–brain barrier that ordinary water-soluble thiamine crosses poorly.

Once absorbed it is converted back to thiamine in the body, so it functions as a centrally-targeted delivery form of vitamin B1 rather than a nutrient in its own right. If the goal is simply to correct or maintain thiamine status, ordinary dietary thiamine — whole grains, pork, legumes, seeds, fortified cereals — does that; sulbutiamine is used specifically when a central effect beyond nutritional repletion is wanted.

Dosage

There is no RDA, AI or Upper Limit for sulbutiamine because it is not an essential nutrient. The doses below are what research has used, not a personal recommendation.

Because the plasma half-life is short (~5 hours), studied regimens use daily and sometimes divided dosing rather than a single large dose. It is fat-soluble, so taking it with a meal containing some fat is reasonable.

These are doses studied in research, not a personal recommendation — and persistent fatigue should be medically evaluated for an underlying cause before self-treating.

Safety

Sulbutiamine is well tolerated in short-term use. The concern that matters is not acute toxicity — it is what happens over time.

Safety at a Glance

✅ Low / no toxicityDrug interactions

• Well tolerated short-term. Side effects in about 0.6% of the 1,772-patient series ^{1Reference 1Shah SN; Sulbutiamine Study Group · 2003ObservationalAdjuvant role of vitamin B analogue (sulbutiamine) with anti-infective treatment in infection associated asthenia — uncontrolled observational studyView study →}.
• Mild adverse effects — headache, nausea, and occasionally agitation, insomnia or anxiety, consistent with its pro-dopaminergic profile.
• Tolerance and compulsive escalation are documented. A case report describes a patient with bipolar disorder escalating intake compulsively, disrupting his psychiatric care ^{10Reference 10Douzenis A et al. · 2006Case reportSulbutiamine, an ‘innocent’ over the counter drug, interferes with therapeutic outcome of bipolar disorder — case reportView study →}. Do not take it open-endedly or in rising doses.
• Flagged in sports doping control as a possible masking or ergogenic agent ^{9Reference 9Sobolevsky T · 2010Sulbutiamine in sports — doping-control analysisView study →} — relevant to any tested athlete.
• Caution with mood disorders, particularly bipolar disorder, and with other stimulants.
• It treats a symptom, not a cause. Persistent asthenia warrants medical evaluation.

Full Safety & Interactions Detail

Sulbutiamine is generally described as well tolerated in short-term use — in the largest series (1,772 patients) side effects occurred in about 0.6% ^{1Reference 1Shah SN; Sulbutiamine Study Group · 2003ObservationalAdjuvant role of vitamin B analogue (sulbutiamine) with anti-infective treatment in infection associated asthenia — uncontrolled observational studyView study →}. Reported adverse effects are usually mild: headache, nausea, and occasionally agitation, insomnia or anxiety, consistent with its mild stimulant and pro-dopaminergic profile.

The dose-limiting and most important concern is not acute toxicity but tolerance and misuse. A published case report describes a patient with bipolar disorder who escalated sulbutiamine intake compulsively, which disrupted his psychiatric care ^{10Reference 10Douzenis A et al. · 2006Case reportSulbutiamine, an ‘innocent’ over the counter drug, interferes with therapeutic outcome of bipolar disorder — case reportView study →} — so it should not be taken open-endedly or in rising doses, and people with bipolar or other mood disorders should be cautious. Because it is a stimulant-type nootropic, combining it with other stimulants or with mood-affecting medication should be discussed with a clinician.

It also appears in sports doping-control samples and may be considered a masking or ergogenic agent, so competitive athletes should treat it as a flagged substance ^{9Reference 9Sobolevsky T · 2010Sulbutiamine in sports — doping-control analysisView study →}.

Scope disclosure. Interactions assessed? Partially — reviewed for stimulant additivity, mood-disorder/bipolar interaction (a documented case), and use alongside cholinesterase inhibitors (studied). Comprehensive drug-interaction screening, including CYP-mediated effects, has not been formally characterised. Pregnancy/lactation assessed? No human safety data — treat as not established. Upper limit established? No UL set, which does not imply that high or long-term intake is safe; long-term dosing is simply uncharacterised.

Pregnancy & Lactation

⚠ Avoid in pregnancy⚠ Avoid while breastfeeding

Avoid unless directed by a clinician. There are no adequate safety data for sulbutiamine in pregnancy or breastfeeding. Absence of reported harm is not evidence of safety — this has simply not been studied in these populations, so it should not be used during pregnancy or lactation without medical supervision.

Related molecules: thiamine (vitamin B1), the parent vitamer sulbutiamine delivers centrally, and vitamin B1 as a straightforward repletion supplement without the central-targeting or stimulant profile. Benfotiamine — a different synthetic (S-acyl) thiamine derivative with a more peripheral profile, studied in diabetic complications — does not have a page here yet.

References

1. Shah SN; Sulbutiamine Study Group (2003). Adjuvant role of vitamin B analogue (sulbutiamine) with anti-infective treatment in infection associated asthenia — uncontrolled observational study. Journal of the Association of Physicians of India. https://pubmed.ncbi.nlm.nih.gov/14710977/
2. Starling-Soares B, Carrera-Bastos P, Bettendorff L. (2020). Role of the synthetic B1 vitamin sulbutiamine on health — review. Journal of Nutrition and Metabolism. https://pubmed.ncbi.nlm.nih.gov/32399290/
3. Ahmed Mahmoud T, Mohamed Abdelhamied L, Badawy AA, et al. (2026). Comparative evaluation of sulbutiamine and imipramine in the treatment of primary nocturnal enuresis — randomized controlled trial. Journal of Pediatric Urology. https://pubmed.ncbi.nlm.nih.gov/42107294/
4. Sevim S, Kaleağası H, Taşdelen B. (2017). Sulbutiamine shows promising results in reducing fatigue in patients with multiple sclerosis — open clinical study. Multiple Sclerosis and Related Disorders. https://pubmed.ncbi.nlm.nih.gov/28755683/
5. Kiew KK, Wan Mohamad WB, Ridzuan A, et al. (2002). Effects of sulbutiamine on diabetic polyneuropathy: an open randomised controlled study in type 2 diabetics. Malaysian Journal of Medical Sciences. https://pubmed.ncbi.nlm.nih.gov/22969314/
6. Ollat H, Laurent B, Bakchine S, et al. (2007). Effects of the association of sulbutiamine with an acetylcholinesterase inhibitor in early stage and moderate Alzheimer disease — randomized double-blind trial. L’Encéphale. https://pubmed.ncbi.nlm.nih.gov/17675917/
7. Trovero F, et al. (2000). Evidence for a modulatory effect of sulbutiamine on glutamatergic and dopaminergic cortical transmissions in the rat brain — animal study. Neuroscience Letters. https://pubmed.ncbi.nlm.nih.gov/10996447/
8. Bizot JC, et al. (2005). Chronic treatment with sulbutiamine improves memory in an object recognition task and reduces some amnesic effects of dizocilpine — animal study. Progress in Neuro-Psychopharmacology & Biological Psychiatry. https://pubmed.ncbi.nlm.nih.gov/15951087/
9. Sobolevsky T, Rodchenkov G (2010). Sulbutiamine in sports — doping-control analysis. Drug Testing and Analysis. https://pubmed.ncbi.nlm.nih.gov/21204296/
10. Douzenis A, Michopoulos I, Lykouras L (2006). Sulbutiamine, an ‘innocent’ over the counter drug, interferes with therapeutic outcome of bipolar disorder — case report. World Journal of Biological Psychiatry. https://pubmed.ncbi.nlm.nih.gov/16861144/
11. Bykov YV, Bekker RA (2022). On the specific treatment of asthenic states: focus on sulbutiamine — review. Terapevticheskii Arkhiv. https://pubmed.ncbi.nlm.nih.gov/36286970/
12. Van Reeth O (1999). Pharmacologic and therapeutic features of sulbutiamine — review. Drugs of Today (Barcelona). https://pubmed.ncbi.nlm.nih.gov/12973384/
13. Dmitriev DG, Gamidov SI, Permiakova OV (2005). Clinical efficacy of the drug enerion in the treatment of patients with psychogenic (functional) erectile dysfunction — clinical trial. Urologiia. https://pubmed.ncbi.nlm.nih.gov/15776829/

View all 13 references▾